Abstract:Objective To evaluate the clinical results of treatment for osteosarcoma of the extremities with adjuvant chemotherapy regimen Methods Sixty seven patients with ⅡB extremity osteosarcoma were treated with the combination of adjuvant chemotherapy regimen and definitive surgery Forty seven of them were male and twenty four were female The mean age of the patients at the time of diagnosis was 20 years (ranged 10～51 years) Sixty four lesions involved the lower extremity, with 45 involving the distal femur, 14 the upper tibia, 3 the upper fibula and 2 the proximal femur; Three involved the upper end of the humerus The study of subtype of osteosarcoma revealed that 51 were osteoblastic, 6 chondroblastic, 5 fibroblastic and 5 the other subtypes The patients were divided into three groups according to the adjuvant chemotherapy regimen given, the first group consisted of 23 cases, who were treated with the combination of the presurgical cisplatin hyperthermic isolated limb perfusion (CDP-HILP) and postoperative chemotherapy; the second group of 20 cases, who were treated with the combination of the presurgical CBP-HILP and postoperative chemotherapy; and the other 24 cases were treated with postoperative chemotherapy alone Twenty nine of the 67 patients treated surgically had limb salvage procedures; 35 had amputations and 3 had Tikhoff-Limbergs surgery Multiple histologic sections were procured and examined from each of the surgical specimens in the patients who were treated with preoperative HILP to determine the effect of chemotherapy All patients were followed from 3 to 9 years, and the data were statistically analeyed using SPSS 7 0 Results Among 67 cases, 41 (61 19%) had relapse free survival(RFS) in 2 years after surgery, 37 (55 22%) had RFS in 3 years after surgery, and RFS probability at 5 years after surgery was 49 56% Log-rank analysis showed no significant difference in RFS probability among the three groups(P=0 517 1), but there was a significant difference in RFS probability between patients who had limb salvage procedure and those had amputation(P=0 009 7) Age, sex, site and subtype were not significant prognostic variables in this group of patients Correction analysis revealed that the RFS probability were not related with the rate of the tumor necrosis (P=0 058) Conclusion The data revealed that 1) The chemotherapy regimen mainly including platinic drugs was effective treatment for osteosarcoma ,and was more simple and less expensive than any previous reported chemotherapy for steosarcoma, 2) CDP of chemotherapy regimen for osteosarcoma, which had more nephritic and audio toxicity could be replaced by CBP , And 3)Whether the preoperative chemotherapy is suitable for the patients in whom amputation is inevitable (based on age ,size, and involvement of local structure) remains unclear

Clinical observation of docetaxel based regimens as the second-line chemotherapy in osteosarcoma

Clinical Observation of Gemcitabine Combined with Docetaxel in the Treatment of Ad-Vanced Recurrent and Metastatic Osteosarcoma

Efficacy of second-line chemotherapy for advanced osteosarcoma

Clinical Study of Weekly Docetaxel As Second Line Therapy to Non-Small Cell Lung Cancer

Clinical observation of docetaxel combined with oxaliplatin as the second-line therapy in advanced NSCLC

The Open, Multicenters, Double-Arms, Randomized, Parallel Controlled Clinical Trial of Lobaplatin or Gemcitabine Combined with Docetaxel As Second-Line Therapy for Advanced Osteosarcoma-the Effectiveness and Safety Analysis.

The investigation of efficacy and dosage of docetaxel as the second-line chemotherapy in non-small cell lung cancer

Clinical observation of gemcitabine in combination with docetaxel in patients with recurrent or refractory osteosarcoma

Efficacy of Docetaxel Single-Agent As Second-Line Treatment for 33 Patients with Advanced Non-Small Cell Lung Cancer

The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy

A Phase II Study of Single-agent Docetaxel Chemotherapy for Non-small Cell Lung Cancer

A Randomized Phase Ⅱ Trial of Docetaxel/ Ifosfamide Regimen Versus Single-Agent Docetaxel in Second-Line Treatment of Advanced Non-Small-cell Lung Cancer

The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre‐clinical study

Efficacy of First-Line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer.

Combined with oxaliplatin or cisplatin in second line treatment of advanced non-small cell lung cancer

[Comparison of Single-Agent Docetaxel Versus Docetaxel Plus Platinum Combination Agent in Second-Line Treatment for Advanced Non-Small Cell Lung Cancer].

EFFICACY OBSERVATION OF SINGLE-AGENT DOCETAXEL VERSUS DOCETAXEL PLUS CISPLATIN AS SECONDLINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER

Combination of Gemcitabine and Docetaxel: a Regimen Overestimated in Refractory Metastatic Osteosarcoma?

The clinical observation of gemcitabine combined with cisplatin as second-line chemotherapy for non-small cell lung cancer

The assessment of the effectiveness of the adjuvant chemotherapy regimen for the treatment of osteosarcoma

Comparison of the Clinical Effects of Paclitaxel and Paclitaxel Plus Oxaliplatin As the Second-line Treatment of Advanced Non-small Cell Lung Cancer